Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ACAD |
---|---|---|
09:32 ET | 7442 | 15.6 |
09:41 ET | 200 | 15.72 |
09:43 ET | 2323 | 15.71 |
09:45 ET | 1100 | 15.685 |
09:48 ET | 1238 | 15.71 |
09:50 ET | 882 | 15.7355 |
09:52 ET | 300 | 15.71 |
09:54 ET | 5487 | 15.74 |
09:56 ET | 2909 | 15.73 |
09:57 ET | 5250 | 15.725 |
09:59 ET | 6074 | 15.7599 |
10:01 ET | 1700 | 15.8 |
10:03 ET | 2199 | 15.82 |
10:06 ET | 2903 | 15.83 |
10:08 ET | 901 | 15.82 |
10:10 ET | 17881 | 15.7795 |
10:12 ET | 2115 | 15.71 |
10:14 ET | 15383 | 15.715 |
10:15 ET | 2291 | 15.735 |
10:17 ET | 2034 | 15.73 |
10:19 ET | 3343 | 15.67 |
10:21 ET | 2300 | 15.675 |
10:24 ET | 1275 | 15.68 |
10:26 ET | 3614 | 15.63 |
10:28 ET | 1770 | 15.64 |
10:30 ET | 2141 | 15.63 |
10:32 ET | 600 | 15.66 |
10:33 ET | 2837 | 15.66 |
10:35 ET | 5667 | 15.655 |
10:37 ET | 1836 | 15.64 |
10:39 ET | 2535 | 15.64 |
10:42 ET | 327 | 15.635 |
10:44 ET | 2604 | 15.66 |
10:46 ET | 1707 | 15.665 |
10:48 ET | 755 | 15.66 |
10:50 ET | 500 | 15.65 |
10:51 ET | 1782 | 15.615 |
10:53 ET | 302 | 15.6075 |
10:55 ET | 400 | 15.6 |
10:57 ET | 3971 | 15.595 |
11:00 ET | 600 | 15.59 |
11:02 ET | 1683 | 15.57 |
11:04 ET | 300 | 15.58 |
11:06 ET | 1100 | 15.59 |
11:08 ET | 849 | 15.58 |
11:09 ET | 700 | 15.565 |
11:11 ET | 1302 | 15.55 |
11:13 ET | 1666 | 15.55 |
11:15 ET | 500 | 15.57 |
11:18 ET | 1253 | 15.57 |
11:20 ET | 1325 | 15.57 |
11:22 ET | 1150 | 15.57 |
11:24 ET | 983 | 15.55 |
11:26 ET | 1100 | 15.54 |
11:27 ET | 1779 | 15.5475 |
11:29 ET | 2207 | 15.545 |
11:31 ET | 400 | 15.54 |
11:33 ET | 100 | 15.535 |
11:36 ET | 4771 | 15.51 |
11:38 ET | 423 | 15.51 |
11:40 ET | 2364 | 15.5 |
11:42 ET | 600 | 15.51 |
11:44 ET | 9639 | 15.485 |
11:45 ET | 2134 | 15.5 |
11:47 ET | 1772 | 15.49 |
11:49 ET | 209 | 15.495 |
11:51 ET | 2514 | 15.485 |
11:54 ET | 813 | 15.48 |
11:56 ET | 200 | 15.47 |
11:58 ET | 2795 | 15.48 |
12:00 ET | 800 | 15.45 |
12:02 ET | 5133 | 15.42 |
12:03 ET | 23253 | 15.405 |
12:05 ET | 14991 | 15.4 |
12:07 ET | 12022 | 15.38 |
12:09 ET | 30553 | 15.395 |
12:12 ET | 12123 | 15.4 |
12:14 ET | 1946 | 15.38 |
12:16 ET | 4659 | 15.395 |
12:18 ET | 4762 | 15.39 |
12:20 ET | 7179 | 15.4 |
12:21 ET | 1225 | 15.38 |
12:23 ET | 7576 | 15.42 |
12:25 ET | 5111 | 15.44 |
12:27 ET | 3643 | 15.445 |
12:30 ET | 600 | 15.445 |
12:32 ET | 5276 | 15.47 |
12:34 ET | 2275 | 15.466622 |
12:36 ET | 4545 | 15.435 |
12:38 ET | 5624 | 15.425 |
12:39 ET | 6334 | 15.4 |
12:41 ET | 16392 | 15.445 |
12:43 ET | 23322 | 15.45 |
12:45 ET | 13378 | 15.46 |
12:48 ET | 2277 | 15.455 |
12:50 ET | 8019 | 15.465 |
12:52 ET | 1412 | 15.46 |
12:54 ET | 3759 | 15.455 |
12:56 ET | 11218 | 15.47 |
12:57 ET | 3469 | 15.515 |
12:59 ET | 1788 | 15.52 |
01:01 ET | 4884 | 15.505 |
01:03 ET | 1567 | 15.46 |
01:06 ET | 3346 | 15.475 |
01:08 ET | 6898 | 15.5 |
01:10 ET | 1162 | 15.49 |
01:12 ET | 7166 | 15.49 |
01:14 ET | 1920 | 15.5 |
01:15 ET | 7609 | 15.4988 |
01:17 ET | 4073 | 15.4808 |
01:19 ET | 3240 | 15.495 |
01:21 ET | 2245 | 15.505 |
01:24 ET | 4626 | 15.5 |
01:26 ET | 1862 | 15.48 |
01:28 ET | 306 | 15.48 |
01:30 ET | 2629 | 15.465 |
01:32 ET | 2674 | 15.465 |
01:33 ET | 100 | 15.465 |
01:35 ET | 480 | 15.465 |
01:37 ET | 3305 | 15.46 |
01:39 ET | 409 | 15.45 |
01:42 ET | 4224 | 15.465 |
01:44 ET | 2092 | 15.485 |
01:46 ET | 2000 | 15.495 |
01:48 ET | 1200 | 15.495 |
01:50 ET | 2461 | 15.495 |
01:51 ET | 272 | 15.495 |
01:53 ET | 6379 | 15.5 |
01:55 ET | 3224 | 15.495 |
01:57 ET | 4370 | 15.48 |
02:00 ET | 4630 | 15.5 |
02:02 ET | 200 | 15.495 |
02:04 ET | 5425 | 15.45 |
02:06 ET | 10312 | 15.45 |
02:08 ET | 9177 | 15.46 |
02:09 ET | 4472 | 15.46 |
02:11 ET | 500 | 15.46 |
02:13 ET | 10486 | 15.42 |
02:15 ET | 11174 | 15.38 |
02:18 ET | 4917 | 15.385 |
02:20 ET | 3651 | 15.38 |
02:22 ET | 3850 | 15.36 |
02:24 ET | 6205 | 15.34 |
02:26 ET | 13482 | 15.35 |
02:27 ET | 6416 | 15.39 |
02:29 ET | 4258 | 15.405 |
02:31 ET | 8254 | 15.35 |
02:33 ET | 3968 | 15.35 |
02:36 ET | 8723 | 15.355 |
02:38 ET | 4653 | 15.38 |
02:40 ET | 3944 | 15.375 |
02:42 ET | 5089 | 15.375 |
02:44 ET | 4945 | 15.36 |
02:45 ET | 4265 | 15.375 |
02:47 ET | 3400 | 15.385 |
02:49 ET | 1506 | 15.405 |
02:51 ET | 5153 | 15.385 |
02:54 ET | 2426 | 15.37 |
02:56 ET | 1165 | 15.36 |
02:58 ET | 7505 | 15.37 |
03:00 ET | 900 | 15.375 |
03:02 ET | 7067 | 15.335 |
03:03 ET | 3233 | 15.35 |
03:05 ET | 2746 | 15.345 |
03:07 ET | 1800 | 15.35 |
03:09 ET | 5330 | 15.365 |
03:12 ET | 6572 | 15.35 |
03:14 ET | 5994 | 15.31 |
03:16 ET | 2901 | 15.305 |
03:18 ET | 2271 | 15.31 |
03:20 ET | 6940 | 15.325 |
03:21 ET | 8869 | 15.33 |
03:23 ET | 6944 | 15.35 |
03:25 ET | 1986 | 15.35 |
03:27 ET | 4474 | 15.335 |
03:30 ET | 2105 | 15.31 |
03:32 ET | 6618 | 15.311 |
03:34 ET | 3200 | 15.315 |
03:36 ET | 7899 | 15.305 |
03:38 ET | 2258 | 15.305 |
03:39 ET | 800 | 15.305 |
03:41 ET | 7481 | 15.301 |
03:43 ET | 10367 | 15.295 |
03:45 ET | 13787 | 15.295 |
03:48 ET | 12024 | 15.305 |
03:50 ET | 20486 | 15.345 |
03:52 ET | 6517 | 15.35 |
03:54 ET | 8020 | 15.37 |
03:56 ET | 15541 | 15.34 |
03:57 ET | 26252 | 15.3875 |
03:59 ET | 451642 | 15.38 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
ACADIA Pharmaceuticals Inc | 2.7B | 84.8x | --- |
Azenta Inc | 2.4B | -17.2x | --- |
PTC Therapeutics Inc | 2.6B | -5.9x | --- |
Guardant Health Inc | 3.3B | -5.6x | --- |
Novavax Inc | 2.2B | -4.6x | --- |
Genmab A/S | 17.4B | 19.5x | +22.71% |
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
---|---|
Revenue (TTM) | $890.5M |
Shares Outstanding | 165.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.39 |
EPS | $0.18 |
Book Value | $2.62 |
P/E Ratio | 84.8x |
Price/Sales (TTM) | 3.0 |
Price/Cash Flow (TTM) | 64.4x |
Operating Margin | 2.56% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.